Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN-Reference-Cited by-同舟云学术

Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Published:2024-05-23 Issue:5 Volume:26 Page:609-617
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Cohen Shlomi^ORCID,Rolandsdotter Helena,Kolho Kaija-Leena,Turner Dan,Tzivinikos Christos,Bramuzzo Matteo,Pujol-Muncunill Gemma,Scarallo Luca,Urlep Darja,Rinawi Firas,Granot Maya,Kang Ben,Longueville Ylva,Rodríguez-Belvís Marta Velasco,Weintraub Yael,Navas-López Víctor Manuel,Yerushalmy-Feler Anat

Funder

Tel Aviv University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40272-024-00631-z.pdf

Reference29 articles.

1. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257–91.

2. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391-399.e1.

3. Croft NM, Faubion WA Jr, Kugathasan S, et al. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2021;6(8):616–27.

4. Breton J, Kastl A, Conrad M, et al. Positioning biologic therapies in the management of pediatric inflammatory bowel disease. Gastroenterol Hepatol. 2020;16:400–14.

5. Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol. 2023;8(1):31–42.